Margaret A. Pax has served as a director of Repligen since March 2024. Ms. Pax brings over 30 years of experience leading the development and execution of growth strategies for global life sciences companies. This includes eight years with Thermo Fisher Scientific, where, from 2016 to 2020, she served as Vice President, Strategy and Innovation for Fisher Clinical Services, the market leader in outsourced clinical trial support services. Her background also includes her position as Senior Director, Corporate Development & Strategy at Thermo Fisher from 2013 to 2016, and Senior Director, Portable Analytical Instrumentation for Thermo Fisher from 2012 to 2013.
From 1989 to 2000, Ms. Pax was with Philips Healthcare, where she held senior leadership roles in Business Development, Marketing and Product Management. She has also held several entrepreneurial leadership positions, including as Vice President, Business and Clinical Development from 2006 to 2011 with Microchips Biomedical, a drug delivery company that was acquired by Dare Bioscience.
From 2023 to 2024, Ms. Pax was an independent board director at Alimera Sciences, a Nasdaq-listed pharmaceutical company acquired by ANI Pharmaceuticals in 2024. She is an independent director of Jellagen, a privately-held UK biomaterials company, and previously sat on the board of the U.S. subsidiary of BioPorto A/S from 2021 to 2024. Ms. Pax holds a B.A. from the College of Holy Cross, and an M.B.A. from Harvard Business School.